Puisis recently spoke with MM+M about the funding raise, the condition of the autoimmune treatment space and the potential of Chicago’s ascendant biotech scene.
Immunovant’s autoimmune drug shines in Phase 1 study, surprises analysts
Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.
Court clears Pfizer to move ahead with Remicade biosimilar; McDonald’s yanks activity trackers over skin irritation; California drug-pricing bill pulled